Title |
Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study
|
---|---|
Published in |
The Journal of Law, Medicine & Ethics, January 2021
|
DOI | 10.1177/1073110516644210 |
Pubmed ID | |
Authors |
Gary E Marchant, Kathryn Scheckel, Doug Campos-Outcalt |
Abstract |
As the health care system transitions to a precision medicine approach that tailors clinical care to the genetic profile of the individual patient, there is a potential tension between the clinical uptake of new technologies by providers and the legal system's expectation of the standard of care in applying such technologies. We examine this tension by comparing the type of evidence that physicians and courts are likely to rely on in determining a duty to recommend pharmacogenetic testing of patients prescribed the oral anti-coagulant drug warfarin. There is a large body of inconsistent evidence and factors for and against such testing, but physicians and courts are likely to weigh this evidence differently. The potential implications for medical malpractice risk are evaluated and discussed. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Scientists | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 21% |
Professor | 3 | 13% |
Student > Bachelor | 3 | 13% |
Student > Master | 3 | 13% |
Researcher | 2 | 8% |
Other | 5 | 21% |
Unknown | 3 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 17% |
Social Sciences | 3 | 13% |
Economics, Econometrics and Finance | 3 | 13% |
Nursing and Health Professions | 2 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Other | 5 | 21% |
Unknown | 5 | 21% |